S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in

Aravive Stock Forecast, Price & News

-0.13 (-2.16 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $5.89
50-Day Range
MA: $5.92
52-Week Range
Now: $5.89
Volume85,373 shs
Average Volume105,114 shs
Market Capitalization$94.75 million
P/E RatioN/A
Dividend YieldN/A
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.


Overall MarketRank

1.64 out of 5 stars

Medical Sector

277th out of 1,928 stocks

Pharmaceutical Preparations Industry

140th out of 774 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARAV



Sales & Book Value

Annual Sales$4.75 million
Book Value$4.71 per share


Net Income$-18,220,000.00


Market Cap$94.75 million
Next Earnings Date3/26/2021 (Estimated)
-0.13 (-2.16 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aravive (NASDAQ:ARAV) Frequently Asked Questions

How has Aravive's stock price been impacted by Coronavirus?

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARAV shares have increased by 18.0% and is now trading at $5.89.
View which stocks have been most impacted by COVID-19

Is Aravive a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aravive?

Wall Street analysts have given Aravive a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aravive wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Aravive's CEO?

1,428 employees have rated Aravive CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Aravive's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for Aravive

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.24.
View Aravive's earnings history

What price target have analysts set for ARAV?

5 Wall Street analysts have issued 12 month price targets for Aravive's stock. Their forecasts range from $20.00 to $30.00. On average, they expect Aravive's stock price to reach $25.00 in the next year. This suggests a possible upside of 324.4% from the stock's current price.
View analysts' price targets for Aravive
or view Wall Street analyst' top-rated stocks.

Who are some of Aravive's key competitors?

What other stocks do shareholders of Aravive own?

Who are Aravive's key executives?

Aravive's management team includes the following people:
  • Dr. Gail F. McIntyre, CEO & Director (Age 57, Pay $453.34k)
  • Mr. Vinay Shah, Chief Financial Officer (Age 58, Pay $463.51k)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 55)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Dr. Randy L. Anderson, Sr. VP of Data Sciences
  • Dr. Reshma Rangwala M.D., Ph.D., Chief Medical Officer
  • Kenneth L. Guernsey, Sec.

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $5.89.

How big of a company is Aravive?

Aravive has a market capitalization of $94.75 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 16 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.